Genmab A/S GMAB.OQ, GMAB.O is expected to show a rise in quarterly revenue when it reports results on February 12 for the period ending December 31 2024
The Valby Denmark-based company is expected to report a 33.1% increase in revenue to $898.762 million from $675.08 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Genmab A/S is for earnings of 28 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Genmab A/S is $35.00, above its last closing price of $19.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 0.35 | 0.35 | 0.29 | Missed | -16.6 |
Jun. 30 2024 | 0.33 | 0.33 | 0.31 | Missed | -5.2 |
Mar. 31 2024 | 0.14 | 1.47 | 0.29 | Missed | -80 |
Dec. 31 2023 | 5.10 | 3.35 | 0.14 | Missed | -95.8 |
Sep. 30 2023 | 3.05 | 3.25 | 0.47 | Missed | -85.5 |
Jun. 30 2023 | 1.66 | 2.16 | 0.30 | Missed | -86.1 |
Mar. 31 2023 | 0.56 | 0.63 | 0.05 | Missed | -92.2 |
Dec. 31 2022 | 3.57 | 3.10 | 0.12 | Missed | -96.1 |
This summary was machine generated February 10 at 16:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)